Nils Berginström, Johan Thelander, Peter Nordström, Anna Nordström
Fatigue is one of the most common symptoms following traumatic brain injury (TBI). Despite its prevalence, fatigue remains a challenging concept to define and measure. The aim of the present study was to explore potential relationships between self-rated fatigue in patients with TBI and performance on several widely used neuropsychological tests. In a cross-sectional design, patients with TBI (n = 68) and healthy controls (n = 27) underwent a comprehensive battery of commonly used neuropsychological tests and completed two self-assessment fatigue scales, the Fatigue Severity Scale and the Mental Fatigue Scale. Patients with TBI performed worse on neuropsychological tests of short-term memory, processing speed and executive functioning (inhibition) compared to healthy controls. Within the TBI group, only the Paced Auditory Serial Addition Test (PASAT) and the Stroop—Inhibition task showed significant correlations with measures of fatigue. However, after adjusting for relevant demographic variables, including age, gender, education and TBI severity, only PASAT remained significantly associated with the Mental Fatigue Scale (r = .45, p = .005). Within the healthy control group, no such associations were found. These results highlight an interesting relationship between PASAT performance and self-assessed fatigue. With further research, PASAT, modifications of it or similar measures could potentially help clinicians in evaluating fatigue in patients with TBI.
{"title":"Among common neuropsychological tests, the Paced auditory serial addition test is the strongest predictor of trait fatigue in patients with traumatic brain injury","authors":"Nils Berginström, Johan Thelander, Peter Nordström, Anna Nordström","doi":"10.1111/jnp.12419","DOIUrl":"10.1111/jnp.12419","url":null,"abstract":"<p>Fatigue is one of the most common symptoms following traumatic brain injury (TBI). Despite its prevalence, fatigue remains a challenging concept to define and measure. The aim of the present study was to explore potential relationships between self-rated fatigue in patients with TBI and performance on several widely used neuropsychological tests. In a cross-sectional design, patients with TBI (<i>n</i> = 68) and healthy controls (<i>n</i> = 27) underwent a comprehensive battery of commonly used neuropsychological tests and completed two self-assessment fatigue scales, the Fatigue Severity Scale and the Mental Fatigue Scale. Patients with TBI performed worse on neuropsychological tests of short-term memory, processing speed and executive functioning (inhibition) compared to healthy controls. Within the TBI group, only the Paced Auditory Serial Addition Test (PASAT) and the Stroop—Inhibition task showed significant correlations with measures of fatigue. However, after adjusting for relevant demographic variables, including age, gender, education and TBI severity, only PASAT remained significantly associated with the Mental Fatigue Scale (<i>r</i> = .45, <i>p</i> = .005). Within the healthy control group, no such associations were found. These results highlight an interesting relationship between PASAT performance and self-assessed fatigue. With further research, PASAT, modifications of it or similar measures could potentially help clinicians in evaluating fatigue in patients with TBI.</p>","PeriodicalId":197,"journal":{"name":"Journal of Neuropsychology","volume":"19 3","pages":"473-485"},"PeriodicalIF":1.8,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bpspsychub.onlinelibrary.wiley.com/doi/epdf/10.1111/jnp.12419","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emma Whooley, Vincent Koppelmans, Hayley J. MacDonald, Alison Hall, Marit F. L. Ruitenberg
Up to 45% of patients with Parkinson's disease (PD) experience impulse control disorders (ICDs), characterized by a loss of voluntary control over impulses, drives or temptations. This study aimed to investigate whether previously identified genetic and psychiatric risk factors interact towards the development of ICDs in PD. A total of 278 de novo PD patients (ICD-free at enrollment) were selected from the Parkinson's Progression Markers Initiative database. ICD presence at baseline and yearly follow-up assessments were evaluated via the Questionnaire for Impulsive-Compulsive Disorders. Symptoms of anxiety and depression at baseline were measured via the State–Trait-Anxiety Inventory and Geriatric Depression Scale, respectively. Furthermore, an individual dopamine genetic risk score was calculated according to polymorphisms in genes coding for dopamine (D1, D2 and D3 receptors and catechol-O-methyltransferase), with higher scores reflecting higher central dopamine neurotransmission. In total, 146 participants (47.5%) developed an ICD with an average onset time of 36 months (range 3–96) from baseline. Results from a Cox proportional hazards model showed a trait anxiety × genetics interaction, suggesting that individuals with both higher baseline trait anxiety scores and higher dopamine genetic risk scores were at increased risk of ICD development. This interaction remained significant after controlling for age, sex and motor symptom severity. Our findings suggest that genetic and psychiatric predictors of impulsivity in PD interact and jointly yield increased ICD risk during the course of the disorder. This implies that early screening of anxiety symptoms in combination with genotyping can be useful to identify those at risk for ICD.
高达45%的帕金森氏症(PD)患者患有冲动控制障碍(ICDs),其特征是失去对冲动、冲动或诱惑的自主控制。本研究旨在调查先前确定的遗传和精神危险因素是否与PD患者的icd发展相互作用。从帕金森进展标志物倡议数据库中选择278名PD患者(入组时无icd)。通过冲动性强迫症问卷评估ICD在基线和年度随访评估中的存在。基线时的焦虑和抑郁症状分别通过状态-特质-焦虑量表和老年抑郁量表进行测量。此外,根据多巴胺编码基因(D1、D2和D3受体和儿茶酚- o -甲基转移酶)的多态性计算个体多巴胺遗传风险评分,得分越高反映中枢多巴胺神经传递越高。共有146名参与者(47.5%)发展为ICD,平均发病时间为36个月(范围3-96个月)。Cox比例风险模型的结果显示,特质焦虑与遗传相互作用,表明基线特质焦虑评分较高和多巴胺遗传风险评分较高的个体发生ICD的风险增加。在控制了年龄、性别和运动症状严重程度后,这种相互作用仍然显著。我们的研究结果表明,PD中冲动性的遗传和精神预测因素相互作用并共同导致疾病过程中ICD风险增加。这意味着早期筛查焦虑症状并结合基因分型可用于识别有ICD风险的人。
{"title":"Dopamine genetic risk scores and psychiatric symptoms: Interacting risk factors for impulse control behaviours in de novo Parkinson's disease","authors":"Emma Whooley, Vincent Koppelmans, Hayley J. MacDonald, Alison Hall, Marit F. L. Ruitenberg","doi":"10.1111/jnp.12415","DOIUrl":"10.1111/jnp.12415","url":null,"abstract":"<p>Up to 45% of patients with Parkinson's disease (PD) experience impulse control disorders (ICDs), characterized by a loss of voluntary control over impulses, drives or temptations. This study aimed to investigate whether previously identified genetic and psychiatric risk factors interact towards the development of ICDs in PD. A total of 278 <i>de novo</i> PD patients (ICD-free at enrollment) were selected from the Parkinson's Progression Markers Initiative database. ICD presence at baseline and yearly follow-up assessments were evaluated via the Questionnaire for Impulsive-Compulsive Disorders. Symptoms of anxiety and depression at baseline were measured via the State–Trait-Anxiety Inventory and Geriatric Depression Scale, respectively. Furthermore, an individual dopamine genetic risk score was calculated according to polymorphisms in genes coding for dopamine (D1, D2 and D3 receptors and catechol-O-methyltransferase), with higher scores reflecting higher central dopamine neurotransmission. In total, 146 participants (47.5%) developed an ICD with an average onset time of 36 months (range 3–96) from baseline. Results from a Cox proportional hazards model showed a trait anxiety × genetics interaction, suggesting that individuals with both higher baseline trait anxiety scores and higher dopamine genetic risk scores were at increased risk of ICD development. This interaction remained significant after controlling for age, sex and motor symptom severity. Our findings suggest that genetic and psychiatric predictors of impulsivity in PD interact and jointly yield increased ICD risk during the course of the disorder. This implies that early screening of anxiety symptoms in combination with genotyping can be useful to identify those at risk for ICD.</p>","PeriodicalId":197,"journal":{"name":"Journal of Neuropsychology","volume":"19 3","pages":"443-453"},"PeriodicalIF":1.8,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143057396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In 1941, André Rey published the Rey Complex Figure, a widely used test for assessing visual-constructional ability and visual memory. It consists of two parts: copy and recall. Evaluating the copy portion presents challenges, as it requires the administrator to focus on both the process and outcome. The assessor must systematically track how the patient copies the figure in real-time to evaluate their planning, organisation and executive abilities. This ‘clinician's copy’ serves as a record of the patient's approach, aiding later judgements about their cognitive skills. To ensure accuracy, clinicians need a method to record this process for later review or colleague consultation. This paper revisits Rey's suggestion of using different coloured pencils to observe the copy sequence, proposing an alternative. Instead of providing coloured pencils to the patient, we recommend that the administrator use them to record the copy sequence. This method aligns with test norms, reducing potential distractions for the patient while enabling both experienced and novice administrators to easily track and document the sequence of copying.
{"title":"Reimagining André Rey's method for recording the copy process of the Rey Complex Figure Test: A commentary","authors":"Maneesh V. Kuruvilla, Angela Blazely","doi":"10.1111/jnp.12414","DOIUrl":"10.1111/jnp.12414","url":null,"abstract":"<p>In 1941, André Rey published the Rey Complex Figure, a widely used test for assessing visual-constructional ability and visual memory. It consists of two parts: copy and recall. Evaluating the copy portion presents challenges, as it requires the administrator to focus on both the process and outcome. The assessor must systematically track how the patient copies the figure in real-time to evaluate their planning, organisation and executive abilities. This ‘clinician's copy’ serves as a record of the patient's approach, aiding later judgements about their cognitive skills. To ensure accuracy, clinicians need a method to record this process for later review or colleague consultation. This paper revisits Rey's suggestion of using different coloured pencils to observe the copy sequence, proposing an alternative. Instead of providing coloured pencils to the patient, we recommend that the administrator use them to record the copy sequence. This method aligns with test norms, reducing potential distractions for the patient while enabling both experienced and novice administrators to easily track and document the sequence of copying.</p>","PeriodicalId":197,"journal":{"name":"Journal of Neuropsychology","volume":"19 3","pages":"649-654"},"PeriodicalIF":1.8,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bpspsychub.onlinelibrary.wiley.com/doi/epdf/10.1111/jnp.12414","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>In the last decade, Alzheimer's disease research has seen large shifts, particularly regarding diagnostic criteria and the use of protein biomarkers. The Alzheimer's Association (AA) workgroup has recently revised their previous 2018 research criteria (Jack Jr et al., <span>2018</span>) for diagnosis and staging of Alzheimer's disease to now inform both research and clinical care (Jack Jr et al., <span>2024a</span>), maintaining a biological definition that primarily relies upon protein biomarkers, such as amyloid and tau levels, to identify the disease even in the absence of cognitive symptoms (e.g. memory and language impairment). In counter-response, the International Working Group (IWG) advocates for an integrative clinical-biological approach, emphasizing that the diagnosis of Alzheimer's disease should not rely solely on protein biomarkers but must also incorporate phenotypic expression such as objective cognitive impairment (Dubois et al., <span>2021</span>, <span>2024</span>).</p><p>The debate over a biological versus clinical-biological definition of Alzheimer's disease has been ongoing for years but was reignited earlier this year after the release of the revised AA criteria (Jack Jr et al., <span>2024a</span>). Petersen et al. (Petersen et al., <span>2024</span>). presented a well-balanced comparison of the overlapping standpoints and differences between the AA and IWG frameworks. Proponents of the biological-only approach have argued that focusing on protein biomarkers, such as amyloid and tau, allows for earlier detection of the disease, providing a window for intervention during the preclinical stage before a significant cognitive decline occurs (Jack Jr et al., <span>2024b</span>). Jack Jr et al (Jack Jr et al., <span>2024a</span>) highlight that protein biomarkers offer a more standardized and objectively replicable framework, reducing the variability seen in clinical assessments alone. Critics of the biological framework point out significant limitations and risks. Many researchers caution that a protein biomarker-only approach may lead to overdiagnosis, unnecessary anxiety and stigma for individuals who may never clinically express the underlying disease pathology (Petersen et al., <span>2024</span>). This perspective reflects concerns about the potential psychological, social and ethical ramifications of labelling asymptomatic individuals as having Alzheimer's disease based purely on protein-biomarker positivity, given the variability in symptom progression and the influence of factors such as cognitive reserve (Glymour et al., <span>2018</span>; Kiselica et al., <span>2024</span>).</p><p>While a positive protein biomarker test may justify a diagnosis of a disease, the debate raises the question of whether this diagnosis should be ‘Alzheimer's disease’, the same label traditionally associated with progressive cognitive decline and underlying neuropathology. Using the same term for asymptomatic individuals with abnormal prote
在过去的十年里,阿尔茨海默病的研究发生了巨大的变化,特别是在诊断标准和蛋白质生物标志物的使用方面。阿尔茨海默病协会(AA)工作组最近修订了他们之前的2018年阿尔茨海默病诊断和分期研究标准(Jack Jr等人,2018),现在为研究和临床护理提供信息(Jack Jr等人,2024a),维持了主要依赖蛋白质生物标志物(如淀粉样蛋白和tau蛋白水平)的生物学定义,即使在没有认知症状(如记忆和语言障碍)的情况下也能识别该疾病。作为回应,国际工作组(IWG)主张采用临床生物学综合方法,强调阿尔茨海默病的诊断不应仅依赖于蛋白质生物标志物,还必须纳入表型表达,如客观认知障碍(Dubois等人,2021,2024)。关于阿尔茨海默病的生物学定义与临床生物学定义的争论已经持续了多年,但在今年早些时候修订的AA标准发布后重新点燃(Jack Jr等,2024a)。Petersen等人(Petersen et al., 2024)。对AA和IWG框架之间重叠的立场和差异进行了平衡的比较。单纯生物疗法的支持者认为,专注于蛋白质生物标志物,如淀粉样蛋白和tau蛋白,可以更早地发现疾病,在显著认知能力下降发生之前的临床前阶段提供干预窗口(Jack Jr等人,2024b)。Jack Jr等人(Jack Jr等人,2024a)强调,蛋白质生物标志物提供了一个更加标准化和客观可复制的框架,减少了单独在临床评估中看到的可变性。生物框架的批评者指出了重大的局限性和风险。许多研究人员警告说,仅使用蛋白质生物标志物可能会导致过度诊断、不必要的焦虑和对可能从未在临床上表达潜在疾病病理的个体的污名化(Petersen et al., 2024)。考虑到症状进展的可变性和认知储备等因素的影响,这一观点反映了对将无症状个体标记为阿尔茨海默病的潜在心理、社会和伦理后果的担忧(Glymour等人,2018;Kiselica et al., 2024)。虽然阳性的蛋白质生物标志物测试可能证明疾病的诊断是正确的,但争论提出了一个问题,即这种诊断是否应该是“阿尔茨海默病”,这一标签传统上与进行性认知能力下降和潜在的神经病理学有关。将相同的术语用于具有异常蛋白质生物标志物的无症状个体和有症状的患者,会产生概念和实践上的困境。AA框架认为,它试图通过区分阿尔茨海默病的病理学和阿尔茨海默病的临床症状来确保科学准确性。然而,当使用一种不同的标签,表明蛋白质生物标志物阳性是一种独特的疾病,是痴呆的危险因素时,这一目标仍然可以实现(Villain &;Planche, 2024)。有效的沟通需要精确的术语,在讨论影响全世界数百万人(包括患者、护理人员、临床医生、研究人员和行业专业人员)的疾病时,几乎没有词汇歧义的余地。相反,为蛋白质生物标志物阳性、无症状的个体建立不同的术语,将强调阿尔茨海默病相关病理的存在,而不意味着临床疾病的存在,这也是IWG提出的(Dubois et al., 2024)。改变阿尔茨海默病的传统概念,而不是为具有异常蛋白质生物标志物的无症状个体采用一个独特的术语,也会使认知和行为评估的关键作用边缘化。虽然蛋白质生物标志物是潜在病理的有价值指标,但认知和行为测量将诊断固定在现实世界的影响中,确保干预措施针对对患者及其家属最重要的事情(Tochel等人,2019)。争论的焦点在于认知症状的缺失是否可以排除阿尔茨海默病的诊断。修订后的AA框架基于以下核心原则:阿尔茨海默病是一个生物过程,在个体无症状时首先由异常蛋白质生物标志物检测到;只有在达到足够的病理负担后,症状才会出现和进展,整个病程可能长达30年(Jack Jr等,2024b)。然而,在正在进行的辩论中,我们似乎很容易放弃“(a)症状”的概念在阿尔茨海默病诊断中的含义。 虽然蛋白质生物标志物领域取得了显著进展,首先是神经成像,最近是基于血液的技术,但主流认知工具仍然依赖于几十年前开发的标准测试。这些标准认知测试包括1975年的迷你精神状态检查(MMSE) (Folstein等人,1975年),1995年的蒙特利尔认知评估(MoCA) (Hobson, 2015年;Nasreddine et al., 2005), 1987年修订的韦氏记忆量表(WMS-R)(韦氏,1987)和1955年修订的韦氏成人智力量表(WAIS)的几个子测试(韦氏,1955),1958年修订的雷伊听觉言语学习测试(RAVLT)(或其概念的变体),以及1983年修订的波士顿命名测试(BNT)(卡普兰等人,1983)。仅从生物学角度来看,认知症状的出现要比神经病理特征的出现晚得多(Jack Jr et al., 2024b),但如果这些症状在神经病理改变的早期阶段就已经出现了呢?多项荟萃分析研究显示,认知健康个体存在与淀粉样蛋白和tau蛋白相关的细微认知障碍(Baker et al., 2017;Pelgrim et al., 2021)。然而,这些症状往往非常微妙,以至于标准的神经心理学测量方法缺乏灵敏度,无法在个体水平上甚至在较小的样本中可靠地检测到这种损害。因此,虽然我们知道认知症状通常在蛋白质生物标志物阳性个体的临床诊断前很多年就会出现,但用标准的神经心理学工具多年来一直未被注意到,在这段时间内将这些个体标记为“无症状”。理论上,临床前阶段的定义是在没有任何临床症状的情况下存在阿尔茨海默病蛋白生物标志物(Dubois et al., 2016;Sperling et al., 2011),而任何细微认知障碍的存在都表明进入前驱期,包括轻度认知障碍状态(Albert et al., 2013;杜布瓦,阿尔伯特,2004;Petersen et al., 2001)。在实践中,认识到认知障碍在临床前阶段是可能的,这使得它的定义有些灵活;如果出现更灵敏的测量仪器,目前由于没有可测量的症状而被指定为“临床前”,当使用更灵敏的工具时,可能会被重新分类为“前驱”。今天被确定为“临床前”的实际上可能包括未被发现的细微认知障碍,模糊了临床痴呆出现之前的临床前和前驱阶段之间的界限。这种界限的模糊强调了改进认知措施的必要性,这些措施可以发现早期变化并改进我们对疾病的分期。尽管正在努力开发更敏感的认知测量方法,但这些创新尚未得到广泛实施,迄今为止临床试验中使用的大多数粗略认知结果测量方法就证明了这一点(Takeshima et al., 2020)。仅基于生物学终点评估治疗,没有明确的表型表达,有可能优先考虑蛋白质生物标志物的变化,而不是患者认知和功能健康的有意义的改善。因此,不应该孤立地看待蛋白质生物标志物,但如前所述,标准的认知测试也不足以在痴呆症的早期阶段评估个体患痴呆症的风险。弥合这一差距对于将AA和IWG框架更紧密地结合在一起至关重要。双方一致认为阿尔茨海默病应及早治疗,并认为阿尔茨海默病蛋白质生物标志物对确定诊断非常重要;他们的主要分歧在于认知障碍在诊断中的作用。提高认知测量的敏感性可以通过在早期阶段识别蛋白质生物标志物和认知异常来帮助调和这些观点,从而在研究中更好地选择临床试验的参与者,并在临床实践中避免恐惧、耻辱和过度治疗。数字时代提供了丰富的机会来加强认知评估,并改善对患者负担相对较低的高危个体的认
{"title":"Time to align sensitive cognitive assessment with protein biomarkers in Alzheimer's disease","authors":"Jet M. J. Vonk","doi":"10.1111/jnp.12413","DOIUrl":"10.1111/jnp.12413","url":null,"abstract":"<p>In the last decade, Alzheimer's disease research has seen large shifts, particularly regarding diagnostic criteria and the use of protein biomarkers. The Alzheimer's Association (AA) workgroup has recently revised their previous 2018 research criteria (Jack Jr et al., <span>2018</span>) for diagnosis and staging of Alzheimer's disease to now inform both research and clinical care (Jack Jr et al., <span>2024a</span>), maintaining a biological definition that primarily relies upon protein biomarkers, such as amyloid and tau levels, to identify the disease even in the absence of cognitive symptoms (e.g. memory and language impairment). In counter-response, the International Working Group (IWG) advocates for an integrative clinical-biological approach, emphasizing that the diagnosis of Alzheimer's disease should not rely solely on protein biomarkers but must also incorporate phenotypic expression such as objective cognitive impairment (Dubois et al., <span>2021</span>, <span>2024</span>).</p><p>The debate over a biological versus clinical-biological definition of Alzheimer's disease has been ongoing for years but was reignited earlier this year after the release of the revised AA criteria (Jack Jr et al., <span>2024a</span>). Petersen et al. (Petersen et al., <span>2024</span>). presented a well-balanced comparison of the overlapping standpoints and differences between the AA and IWG frameworks. Proponents of the biological-only approach have argued that focusing on protein biomarkers, such as amyloid and tau, allows for earlier detection of the disease, providing a window for intervention during the preclinical stage before a significant cognitive decline occurs (Jack Jr et al., <span>2024b</span>). Jack Jr et al (Jack Jr et al., <span>2024a</span>) highlight that protein biomarkers offer a more standardized and objectively replicable framework, reducing the variability seen in clinical assessments alone. Critics of the biological framework point out significant limitations and risks. Many researchers caution that a protein biomarker-only approach may lead to overdiagnosis, unnecessary anxiety and stigma for individuals who may never clinically express the underlying disease pathology (Petersen et al., <span>2024</span>). This perspective reflects concerns about the potential psychological, social and ethical ramifications of labelling asymptomatic individuals as having Alzheimer's disease based purely on protein-biomarker positivity, given the variability in symptom progression and the influence of factors such as cognitive reserve (Glymour et al., <span>2018</span>; Kiselica et al., <span>2024</span>).</p><p>While a positive protein biomarker test may justify a diagnosis of a disease, the debate raises the question of whether this diagnosis should be ‘Alzheimer's disease’, the same label traditionally associated with progressive cognitive decline and underlying neuropathology. Using the same term for asymptomatic individuals with abnormal prote","PeriodicalId":197,"journal":{"name":"Journal of Neuropsychology","volume":"19 2","pages":"172-175"},"PeriodicalIF":1.8,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jnp.12413","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142997082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aims to demonstrate that children and adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who exhibit autism traits have a more severe clinical profile in terms of emotion regulation, clinical features related to ADHD, and functionality, compared to those diagnosed with ADHD without these traits. 50 patients with and 64 patients without autism traits between the ages of 8–16 were recruited for the study among the children and adolescents diagnosed with ADHD. The Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version, DSM-5-2016-Turkish Adaptation (K-SADS-PL-DSM-5-T) was used to exclude the diagnosis of Autism Spectrum Disorder (ASD) and detect comorbid psychiatric diagnosis. The Social Reciprocity Scale (SRS) was completed by parents to determine groups based on autism traits. Children completed the Childhood Anxiety Sensitivity Index (CASI) and the Affective Reactivity Index (ARI). The Strengths and Difficulties Questionnaire (SDQ), Affective Reactivity Index-Parent Report (ARI-P) and Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P) were completed by the parents. We found that the group with autism traits had significantly more hyperactivity/inattention, conduct problems, emotional problems, and peer problems and significantly more irritability and frequent separation anxiety disorder. Although there was no significant impairment in functionality in either group, the level of impairment was significantly higher in the group with autism traits. Children diagnosed with Attention Deficit Hyperactivity Disorder who exhibit autism traits experience higher levels of irritability and separation anxiety disorder, as well as greater impairment in functionality, compared to those without these traits.
{"title":"Comparison of children and adolescents diagnosed with attention deficit hyperactivity disorder with and without autism traits in terms of emotion regulation, clinical characteristics and functionality","authors":"Buket Kılıç, Sadriye E. Ç. Kültür","doi":"10.1111/jnp.12411","DOIUrl":"10.1111/jnp.12411","url":null,"abstract":"<p>This study aims to demonstrate that children and adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who exhibit autism traits have a more severe clinical profile in terms of emotion regulation, clinical features related to ADHD, and functionality, compared to those diagnosed with ADHD without these traits. 50 patients with and 64 patients without autism traits between the ages of 8–16 were recruited for the study among the children and adolescents diagnosed with ADHD. The Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version, DSM-5-2016-Turkish Adaptation (K-SADS-PL-DSM-5-T) was used to exclude the diagnosis of Autism Spectrum Disorder (ASD) and detect comorbid psychiatric diagnosis. The Social Reciprocity Scale (SRS) was completed by parents to determine groups based on autism traits. Children completed the Childhood Anxiety Sensitivity Index (CASI) and the Affective Reactivity Index (ARI). The Strengths and Difficulties Questionnaire (SDQ), Affective Reactivity Index-Parent Report (ARI-P) and Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P) were completed by the parents. We found that the group with autism traits had significantly more hyperactivity/inattention, conduct problems, emotional problems, and peer problems and significantly more irritability and frequent separation anxiety disorder. Although there was no significant impairment in functionality in either group, the level of impairment was significantly higher in the group with autism traits. Children diagnosed with Attention Deficit Hyperactivity Disorder who exhibit autism traits experience higher levels of irritability and separation anxiety disorder, as well as greater impairment in functionality, compared to those without these traits.</p>","PeriodicalId":197,"journal":{"name":"Journal of Neuropsychology","volume":"19 3","pages":"425-442"},"PeriodicalIF":1.8,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In recognising emotions expressed by others, one can make use of both embodied cognition and mechanisms that do not necessarily require activation of the limbic system, such as evoking from memory the meaning of morphological features of the observed face. Instead, we believe that the recognition of the authenticity of an emotional expression is primarily based on embodied cognition, for which the mirror system would play a significant role. To verify this hypothesis, we submitted 20 parkinsonian patients and 20 healthy control subjects to the Emotional Authenticity Recognition test, a novel test using dynamic stimuli to evaluate the ability to recognise emotions and their authenticity. Analysis of variance of the test scores shows that Parkinsonian patients perform worse than controls when they had to recognise the authenticity of emotions, although they are able to identify them. Our results confirm a deficit in the recognition of the authenticity of emotions in patients with Parkinson's disease attributable to the disruption of extrapiramidal limbic circuit between ventral striatum and orbitomesial-prefrontal cortex.
{"title":"Are patients with Parkinson's disease impaired in the recognition of emotion's authenticity?","authors":"Agnese Anzani, Stefano Zago, Teresa Difonzo, Cristina Scarpazza, Nadia Bolognini, Giulia Franco, Alessio Difonzo, Maria Cristina Saetti","doi":"10.1111/jnp.12410","DOIUrl":"10.1111/jnp.12410","url":null,"abstract":"<p>In recognising emotions expressed by others, one can make use of both embodied cognition and mechanisms that do not necessarily require activation of the limbic system, such as evoking from memory the meaning of morphological features of the observed face. Instead, we believe that the recognition of the authenticity of an emotional expression is primarily based on embodied cognition, for which the mirror system would play a significant role. To verify this hypothesis, we submitted 20 parkinsonian patients and 20 healthy control subjects to the Emotional Authenticity Recognition test, a novel test using dynamic stimuli to evaluate the ability to recognise emotions and their authenticity. Analysis of variance of the test scores shows that Parkinsonian patients perform worse than controls when they had to recognise the authenticity of emotions, although they are able to identify them. Our results confirm a deficit in the recognition of the authenticity of emotions in patients with Parkinson's disease attributable to the disruption of extrapiramidal limbic circuit between ventral striatum and orbitomesial-prefrontal cortex.</p>","PeriodicalId":197,"journal":{"name":"Journal of Neuropsychology","volume":"19 3","pages":"411-424"},"PeriodicalIF":1.8,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bpspsychub.onlinelibrary.wiley.com/doi/epdf/10.1111/jnp.12410","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142891079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Understanding the relative contribution of various factors influencing initial severity of aphasia and recovery after a stroke is essential for optimising neurorehabilitation programmes. We investigated how various significant sociodemographic, cognitive, clinical, stroke-related and rehabilitation-related factors modulate aphasia severity and language recovery following left-hemispheric stroke. Employing an innovative method, we conducted a retrospective analysis of 96 stroke participants to explore the combined impact of these factors. The initial severity of aphasia was categorised into severe, mild/moderate and no aphasia based on the severity of their language deficits in the subacute phase (Aphasia Severity Rating Scale, ASRS). To assess speech-and-language recovery, we classified 53/96 patients with aphasia into high and poor recovery categories using a gain score formula (ASRS_discharge—ASRS_admission)/ASRS_admission. Subsequently, we performed statistical analyses (univariate analyses and forward stepwise logistic regression combined with bootstrap) to identify the determinants of the initial severity of aphasia and the degree of recovery. Our analyses unveiled that more severe aphasia initially was correlated with a more severe stroke (Odds Ratio, OR = .90, p = .041), moderate/severe executive dysfunction (OR = .068, p < .001) and larger lesion size (OR = .068, p < .001). Furthermore, the degree of recovery was associated with the intensity of speech-and-language therapy (OR = 1.47, p = .043). These findings enrich our understanding of the determinants of aphasia severity and language recovery, employing an original methodology to scrutinise the collective effect of multiple variables in a retrospective analysis of stroke participants. A better knowledge of these factors may help implement personalised language rehabilitation programmes to maximise speech-and-language recovery.
了解影响失语初始严重程度和中风后恢复的各种因素的相对贡献对于优化神经康复方案至关重要。我们调查了各种重要的社会人口统计学、认知、临床、卒中相关和康复相关因素如何调节左半球卒中后失语严重程度和语言恢复。采用一种创新的方法,我们对96名中风患者进行了回顾性分析,以探讨这些因素的综合影响。根据亚急性期语言缺陷的严重程度,将失语症的初始严重程度分为严重、轻度/中度和无失语症(失语症严重程度评定量表,ASRS)。为了评估言语和语言的恢复情况,我们使用获得评分公式(asrs_出院- asrs_入院)/ asrs_入院将53/96名失语症患者分为恢复高和恢复差两类。随后,我们进行了统计分析(单变量分析和前向逐步逻辑回归结合bootstrap),以确定失语的初始严重程度和恢复程度的决定因素。我们的分析表明,更严重的失语最初与更严重的中风相关(优势比,OR =。90, p = .041),中度/重度执行功能障碍(OR =。068页
{"title":"Multifactorial interplay on language recovery following left-hemispheric stroke: A retrospective study","authors":"Célise Haldin, Shenhao Dai, Céline Piscicelli, Valérie Marcon, Hélène Lœvenbruck, Dominic Pérennou, Monica Baciu","doi":"10.1111/jnp.12406","DOIUrl":"10.1111/jnp.12406","url":null,"abstract":"<p>Understanding the relative contribution of various factors influencing initial severity of aphasia and recovery after a stroke is essential for optimising neurorehabilitation programmes. We investigated how various significant sociodemographic, cognitive, clinical, stroke-related and rehabilitation-related factors modulate aphasia severity and language recovery following left-hemispheric stroke. Employing an innovative method, we conducted a retrospective analysis of 96 stroke participants to explore the combined impact of these factors. The initial severity of aphasia was categorised into severe, mild/moderate and no aphasia based on the severity of their language deficits in the subacute phase (Aphasia Severity Rating Scale, ASRS). To assess speech-and-language recovery, we classified 53/96 patients with aphasia into high and poor recovery categories using a gain score formula (ASRS_discharge—ASRS_admission)/ASRS_admission. Subsequently, we performed statistical analyses (univariate analyses and forward stepwise logistic regression combined with bootstrap) to identify the determinants of the initial severity of aphasia and the degree of recovery. Our analyses unveiled that more severe aphasia initially was correlated with a more severe stroke (Odds Ratio, OR = .90, <i>p</i> = .041), moderate/severe executive dysfunction (OR = .068, <i>p</i> < .001) and larger lesion size (OR = .068, <i>p</i> < .001). Furthermore, the degree of recovery was associated with the intensity of speech-and-language therapy (OR = 1.47, <i>p</i> = .043). These findings enrich our understanding of the determinants of aphasia severity and language recovery, employing an original methodology to scrutinise the collective effect of multiple variables in a retrospective analysis of stroke participants. A better knowledge of these factors may help implement personalised language rehabilitation programmes to maximise speech-and-language recovery.</p>","PeriodicalId":197,"journal":{"name":"Journal of Neuropsychology","volume":"19 2","pages":"256-273"},"PeriodicalIF":1.8,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jnp.12406","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elisa Pini, Fulvio Pepe, Veronica Laini, Nicoletta Ciccarelli, Eugenio Magni
Stroke causes severe long-term disabilities with a significant reduction in quality of life. This study aims to explore the predictive value of cognitive screening in the acute phase of mild stroke on patients' functional outcome after discharge. A total of 110 patients with mild stroke were recruited. Patients were included in the study if they were discharged directly home from the acute units. The cognitive profile of patients was assessed with the Oxford Cognitive Screen (OCS). The OCS was administered 3–10 days after stroke, providing a five domain-specific cognitive profile. Long-term functional outcomes were evaluated by the Stroke Impact Scale 3.0 (SIS 3.0), a self-reported questionnaire that includes physical, cognitive, emotional and social participation dimensions. All patients completed the survey online on average 10 months after stroke. Our results show that OCS is positively associated with physical and cognitive dimensions, after adjusting for age and stroke severity measured by NIHSS at admission. In conclusion, OCS in acute mild stroke seems to be an independent predictor of long-term functional outcomes and could help clinicians in the long-term management of patients.
{"title":"Early neuropsychological screening and long-term functional outcome in a sample of patients affected by mild stroke: The ReSCog Project","authors":"Elisa Pini, Fulvio Pepe, Veronica Laini, Nicoletta Ciccarelli, Eugenio Magni","doi":"10.1111/jnp.12408","DOIUrl":"10.1111/jnp.12408","url":null,"abstract":"<p>Stroke causes severe long-term disabilities with a significant reduction in quality of life. This study aims to explore the predictive value of cognitive screening in the acute phase of mild stroke on patients' functional outcome after discharge. A total of 110 patients with mild stroke were recruited. Patients were included in the study if they were discharged directly home from the acute units. The cognitive profile of patients was assessed with the Oxford Cognitive Screen (OCS). The OCS was administered 3–10 days after stroke, providing a five domain-specific cognitive profile. Long-term functional outcomes were evaluated by the Stroke Impact Scale 3.0 (SIS 3.0), a self-reported questionnaire that includes physical, cognitive, emotional and social participation dimensions. All patients completed the survey online on average 10 months after stroke. Our results show that OCS is positively associated with physical and cognitive dimensions, after adjusting for age and stroke severity measured by NIHSS at admission. In conclusion, OCS in acute mild stroke seems to be an independent predictor of long-term functional outcomes and could help clinicians in the long-term management of patients.</p>","PeriodicalId":197,"journal":{"name":"Journal of Neuropsychology","volume":"19 2","pages":"286-298"},"PeriodicalIF":1.8,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142875846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}